These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31696598)

  • 1. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
    Dejgaard TF; Schmidt S; Frandsen CS; Vistisen D; Madsbad S; Andersen HU; Nørgaard K
    Diabetes Obes Metab; 2020 Apr; 22(4):492-500. PubMed ID: 31696598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
    Dejgaard TF; Knop FK; Tarnow L; Frandsen CS; Hansen TS; Almdal T; Holst JJ; Madsbad S; Andersen HU
    BMJ Open; 2015 Apr; 5(4):e007791. PubMed ID: 25838513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
    Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
    Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
    BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
    Kuhadiya ND; Dhindsa S; Ghanim H; Mehta A; Makdissi A; Batra M; Sandhu S; Hejna J; Green K; Bellini N; Yang M; Chaudhuri A; Dandona P
    Diabetes Care; 2016 Jun; 39(6):1027-35. PubMed ID: 27208343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
    Frandsen CS; Dejgaard TF; Andersen HU; Holst JJ; Hartmann B; Thorsteinsson B; Madsbad S
    Diabetes Obes Metab; 2017 Jun; 19(6):773-782. PubMed ID: 27868372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
    Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
    Dubé MC; D'Amours M; Weisnagel SJ
    Diabetes Obes Metab; 2018 Jan; 20(1):178-184. PubMed ID: 28722271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss.
    Ghanim H; Batra M; Green K; Abuaysheh S; Hejna J; Makdissi A; Borowski R; Kuhadiya ND; Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2020 Oct; 22(10):1742-1752. PubMed ID: 32424935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
    Johansen NJ; Dejgaard TF; Lund A; Vilsbøll T; Andersen HU; Knop FK
    BMJ Open; 2018 Jun; 8(6):e021861. PubMed ID: 29950475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
    Kaku K; Rasmussen MF; Clauson P; Seino Y
    Diabetes Obes Metab; 2010 Apr; 12(4):341-7. PubMed ID: 20380655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
    Lane W; Weinrib S; Rappaport J; Hale C
    Diabetes Obes Metab; 2014 Sep; 16(9):827-32. PubMed ID: 24589127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
    Ahrén B; Hirsch IB; Pieber TR; Mathieu C; Gómez-Peralta F; Hansen TK; Philotheou A; Birch S; Christiansen E; Jensen TJ; Buse JB;
    Diabetes Care; 2016 Oct; 39(10):1693-701. PubMed ID: 27493132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge.
    Pasquel FJ; Urrutia MA; Cardona S; Coronado KWZ; Albury B; Perez-Guzman MC; Galindo RJ; Chaudhuri A; Iacobellis G; Palacios J; Farias JM; Gomez P; Anzola I; Vellanki P; Fayfman M; Davis GM; Migdal AL; Peng L; Umpierrez GE
    Diabetes Obes Metab; 2021 Jun; 23(6):1351-1360. PubMed ID: 33591621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
    Rodbard HW; Bode BW; Harris SB; Rose L; Lehmann L; Jarlov H; Thurman J;
    Diabet Med; 2017 Feb; 34(2):189-196. PubMed ID: 27589252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Torffvit O; Pehrsson NG
    Prim Care Diabetes; 2015 Feb; 9(1):15-22. PubMed ID: 25175385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Kielgast U; Størling J; Overgaard AJ; Svane MS; Olsen MH; Thorsteinsson B; Andersen HU; Krarup T; Holst JJ; Madsbad S
    Diabetes Obes Metab; 2024 Nov; 26(11):4905-4915. PubMed ID: 39192527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.